Kala Pharmaceutic…
USUSDKala Pharmaceuticals Inc (US:KALA) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- kalarx.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- Waltham, United States
- PDG
- Avi Minkowitz
- Employés
- 6
- Fondée
- 2009
- Actions en circulation
- 19.34 M au 2026-08-14
- Flottant
- 19.34 M
- Capitalisation boursière
- 5.68 M USD
- Initiés
- 1.24%
- Investisseurs institutionnels
- 4.07%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- FCF
- —
- Dette
- 26.9 M USD
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Vanguard Capital Managem… | 1.14% | 220 623 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.14% | 220 623 | 2026-06-30 |
| Geode Capital Management… | 0.75% | 145 152 | 2026-06-30 |
| IWICKI MARK T. (Director… | ≈0.54% | 103 540 | 2025-10-23 |
| Vanguard Fiduciary Trust… | 0.52% | 101 396 | 2026-06-30 |
| Fidelity Concord Street… | 0.5% | 96 492 | 2026-07-31 |
| State Street Corporation | 0.46% | 88 570 | 2026-06-30 |
| Blackrock Inc. | 0.37% | 71 542 | 2026-06-30 |
| Northern Trust Corporati… | 0.22% | 41 606 | 2026-06-30 |
| KHARABI DARIUS (Officer) | ≈0.22% | 41 760 | 2025-10-22 |
| BRAZZELL ROMULUS KIM (Of… | ≈0.19% | 35 952 | 2025-10-22 |
| BAZEMORE TODD M (Directo… | ≈0.19% | 35 933 | 2025-10-22 |
| REUMUTH MARY (Chief Fina… | ≈0.15% | 28 906 | 2025-10-23 |
| Fidelity Concord Street… | 0.1% | 19 197 | 2026-07-31 |
| Fidelity Concord Street… | 0.09% | 17 397 | 2026-07-31 |
| KOVEN ANDREW IAN (Direct… | ≈0.09% | 16 972 | 2025-06-13 |
| ROSEN HOWARD B (Director… | ≈0.09% | 16 502 | 2025-06-13 |
| Fidelity Concord Street… | 0.07% | 12 832 | 2026-07-31 |
| PERRY GREGORY D (Directo… | ≈0.07% | 13 344 | 2025-06-13 |
| Qube Research & Technolo… | 0.06% | 11 073 | 2026-06-30 |
| Goldman Sachs Group Inc | 0.06% | 10 921 | 2026-06-30 |
| MYERS CHARLES DANIEL (Di… | ≈0.05% | 10 374 | 2025-06-13 |
| UBS Group AG | 0.05% | 9 057 | 2026-06-30 |
| Tower Research Capital L… | 0% | 616 | 2026-06-30 |
| John Hancock Variable In… | 0% | 355 | 2026-06-30 |
| BAKER BROS ADVISORS, L.P… | — | — | 2025-10-01 |
